Literature DB >> 22611453

The treatment of climacteric symptoms.

Olaf Ortmann1, Claus Lattrich.   

Abstract

BACKGROUND: Peri- and postmenopausal women commonly suffer from climacteric symptoms. In this article, we provide information to help physicians recognize climacteric symptoms and treat them appropriately.
METHODS: The information presented here is based on a selective search of the literature for pertinent articles that appeared from 2008 to early 2011, including the German S3 guideline on hormone therapy (HT) during and after menopause, which was published in 2009.
RESULTS: Perimenopausal women often suffer from climacteric symptoms. Typically, women undergoing menopause complain of heat waves and vaginal dryness. According to randomized controlled trials as well as national and international guidelines, HT is the most effective treatment for vasomotor symptoms and also improves vulvovaginal atrophy; for the latter indication, HT is preferably administered locally. Vaginal estrogen therapy lowers the frequency of recurrent urinary tract infections. However, HT is associated with an increased risk for a number of diseases, including stroke, thromboembolic events, gall-bladder diseases, and breast cancer. Alternative treatments for climacteric symptoms have little or no efficacy.
CONCLUSION: HT should only be used to treat climacteric symptoms after extensive patient education about its benefits and risks. Participatory decision-making is desirable. The generalized use of HT by all women with climacteric symptoms cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611453      PMCID: PMC3355503          DOI: 10.3238/arztebl.2012.0316

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  33 in total

1.  Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2007

2.  Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.

Authors:  Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel
Journal:  Menopause       Date:  2008 Jul-Aug       Impact factor: 2.953

Review 3.  Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.

Authors:  C Perrotta; M Aznar; R Mejia; X Albert; C W Ng
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

4.  Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Authors:  Vanessa M Barnabei; Barbara B Cochrane; Aaron K Aragaki; Ingrid Nygaard; R Stan Williams; Peter G McGovern; Ronald L Young; Ellen C Wells; Mary Jo O'Sullivan; Bertha Chen; Robert Schenken; Susan R Johnson
Journal:  Obstet Gynecol       Date:  2005-05       Impact factor: 7.661

5.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.

Authors:  F Grodstein; P A Newcomb; M J Stampfer
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

6.  Duration of menopausal hot flushes and associated risk factors.

Authors:  Ellen W Freeman; Mary D Sammel; Hui Lin; Ziyue Liu; Clarisa R Gracia
Journal:  Obstet Gynecol       Date:  2011-05       Impact factor: 7.661

7.  Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version.

Authors:  Olaf Ortmann; Martina Dören; Eberhard Windler
Journal:  Arch Gynecol Obstet       Date:  2011-03-24       Impact factor: 2.344

8.  Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Authors:  Ross L Prentice; Joann E Manson; Robert D Langer; Garnet L Anderson; Mary Pettinger; Rebecca D Jackson; Karen C Johnson; Lewis H Kuller; Dorothy S Lane; Jean Wactawski-Wende; Robert Brzyski; Matthew Allison; Judith Ockene; Gloria Sarto; Jacques E Rossouw
Journal:  Am J Epidemiol       Date:  2009-05-25       Impact factor: 4.897

Review 9.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  J Suckling; A Lethaby; R Kennedy
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

View more
  7 in total

1.  Correspondence (letter to the editor): Do not forget estrogen therapy.

Authors:  Matthias J Wenderlein
Journal:  Dtsch Arztebl Int       Date:  2012-10-19       Impact factor: 5.594

Review 2.  Botanical modulation of menopausal symptoms: mechanisms of action?

Authors:  Atieh Hajirahimkhan; Birgit M Dietz; Judy L Bolton
Journal:  Planta Med       Date:  2013-02-13       Impact factor: 3.352

3.  Effects of Inhalation of Essential Oil of Citrus aurantium L. var. amara on Menopausal Symptoms, Stress, and Estrogen in Postmenopausal Women: A Randomized Controlled Trial.

Authors:  Seo Yeon Choi; Purum Kang; Hui Su Lee; Geun Hee Seol
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-12       Impact factor: 2.629

4.  Effect of a gel containing pilocarpine on vaginal atrophy in castrated rats.

Authors:  Cristina A de Sousa-Lages; Lívio P de Deus-Lages; Gabriela V de Sousa; Adinaide C de Moura-Leal; Airton Mendes Conde; Danylo Rafhael Costa-Silva; Maria da Conceição Barros-Oliveira; Carine Soares Borges; Carla Solange Escórcio-Dourado; Fabiane A Sampaio; Lívio C Cunha-Nunes; Benedito B da-Silva
Journal:  Clinics (Sao Paulo)       Date:  2016-05       Impact factor: 2.365

Review 5.  Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches.

Authors:  Rodolfo Pinto-Almazán; Julia J Segura-Uribe; Eunice D Farfán-García; Christian Guerra-Araiza
Journal:  Biomed Res Int       Date:  2017-01-16       Impact factor: 3.411

6.  Heat Shock Protein 60 Antibodies Are Associated With a Risk Factor for Cardiovascular Disease in Bedridden Elderly Patients.

Authors:  Jonas Bernardes de Lima Filho; Letícia Freire; Eliana Aguiar Petri Nahas; Fábio Lera Orsatti; Claudio Lera Orsatti
Journal:  Front Mol Biosci       Date:  2020-06-12

7.  Effects of herbal medicine (Danggwijagyaksan) for treating climacteric syndrome with a blood-deficiency-dominant pattern: A randomized, double-blind, placebo-controlled pilot trial.

Authors:  Eun-Ji Park; Seon-Eun Baek; Mikyung Kim; Ae-Ran Kim; Hyo-Ju Park; Ojin Kwon; Jun-Hwan Lee; Jeong-Eun Yoo
Journal:  Integr Med Res       Date:  2021-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.